Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strontium-89 with Chemohormonal Therapy in Prostate Cancer
NCT00081159Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2004
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of strontium-89 in prostate cancer (PCa) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression Free Survival at 90 months. Started Jul 2004; status: completed.
02
Drugs
strontium-89
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00081159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081159.